Clinical Observation of Paclitaxel Liposome Combined with Cisplatin in the Treatment of Advanced Non-small-cell Lung Cancer

Objective To evaluate the efficacy and toxity of paclitaxel liposome plus cisplatine in the treatment of advanced non-small cell lung cancer.Methods Paclitaxel liposome 135 mg/m2 as a 3h infusion on day 1 and cisplatine 25 mg/m2 as a infusion on day 1 to 3.Treatment was repeated every 21 day.Treatment efficacy was evaluated every two cycles based on the RESIST standard.Results Patients received total of 138 cycles of treatment.The overall response rate was 37.2%,no case achieved complete responces,16 achieved partial responces,20 had stable disease,7 had progression disease.Main adverse reactions were myelosuppression,gastrointestinal toxicity and peripheral neuropathy.the primary myelosuppression was hypoleukia and 3~4 grade rate was 32.6%.The gastrointestinal and peripheral toxicity were mild.No occurrence of hypersensitivity and treatment related death.Conclusion Paclitaxel liposome plus cisplatine regimen is effective and well tolerated in patients with advanced non-small cell lung cancer.